Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 9/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.44 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.44 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.44 |
| ▸ | GNPAT | O15228 | 1/20 | 0.42 |
| ▸ | FNTA | P49354 | 2/20 | 0.38 |
| ▸ | FNTB | P49356 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12118226 | 1.00 | NOD1 (0.53) | NOD1FOLH1NAALAD2RIMKLAGNPAT | |
| SCHEMBL21440846 | 1.00 | NOD1 (0.53) | NOD1FOLH1NAALAD2RIMKLAGNPAT | |
| SCHEMBL13377667 | 1.00 | NOD1 (0.53) | NOD1FOLH1NAALAD2RIMKLAGNPAT | |
| SCHEMBL21242989 | 1.00 | NOD1 (0.53) | NOD1FOLH1NAALAD2RIMKLAGNPAT | |
| SCHEMBL21242721 | 1.00 | NOD1 (0.53) | NOD1FOLH1NAALAD2RIMKLAGNPAT | |
| SCHEMBL23875397 | 0.89 | FOLH1 (0.47) | NOD1FOLH1NAALAD2RIMKLAGNPAT | |
| SCHEMBL12118214 | 0.89 | FOLH1 (0.43) | NOD1FOLH1NAALAD2RIMKLAFNTA | |
| SCHEMBL22111315 | 0.89 | FOLH1 (0.43) | NOD1FOLH1NAALAD2RIMKLAFNTA | |
| SCHEMBL71800 | 0.89 | FOLH1 (0.43) | NOD1FOLH1NAALAD2RIMKLAFNTA | |
| SCHEMBL14478725 | 0.87 | NOD1 (0.54) | NOD1FOLH1NAALAD2RIMKLAGNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143604-A1 | QW DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20220135638-A1 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-05-05 | — | — | US | disclosed |
| US-20220016215-A1 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-20 | — | — | US | disclosed |
| US-11174301-B2 | Peptide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-16 | — | — | US | disclosed |
| US-20200140505-A1 | PEPTIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2020-05-07 | — | — | US | disclosed |
| US-10435445-B2 | Peptide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200140505-A1 | PEPTIDE COMPOUND | GIPR, GLP1R, GRPR | NOD1 2042/4885FOLH1 566/4885NAALAD2 1096/4885 |
| US-20220016215-A1 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | GIPR, GLP1R, GRPR | NOD1 3126/4885FOLH1 1327/4885NAALAD2 3255/4885 |
| US-20230143604-A1 | QW DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | GIPR, GLP1R, GRPR | NOD1 2186/4885FOLH1 736/4885NAALAD2 1789/4885 |
| US-11174301-B2 | Peptide compound | GIPR, GLP1R, GRPR | NOD1 2042/4885FOLH1 566/4885NAALAD2 1096/4885 |
| US-10435445-B2 | Peptide compound | GIPR, GLP1R, GRPR | NOD1 1825/4885FOLH1 551/4885NAALAD2 1192/4885 |
| US-20220135638-A1 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | GIPR, GLP1R, VIPR1 | NOD1 1471/4885FOLH1 1590/4885NAALAD2 2478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.